dear
editor
recent
publish
paper
zhang
et
drug
de
develop
ther
author
evalu
role
signal
transduc
activ
transcript
antifibrot
activ
paclitaxel
vitro
mice
report
treatment
paclitaxel
reduc
level
phosphoryl
dose
timedepend
manner
downregul
express
fibronectin
muscl
actin
collagen
cultur
rat
renal
interstiti
fibroblast
cell
deriv
normal
kidney
treatment
cell
select
inhibitor
mm
suppress
express
fibronectin
collagen
cell
howev
treatment
increas
express
phosphoryl
affect
phosphoryl
immunoprecipit
assay
reveal
paclitaxel
inhibit
activ
disrupt
bind
tubulin
independ
effect
phosphoryl
inhibit
nucleu
furthermor
paclitaxel
treatment
intraperiton
inject
mgkg
twice
week
amelior
renal
interstiti
fibrosi
inhibit
express
fibronectin
collagen
male
mous
model
unilater
ureter
obstruct
paclitaxel
administr
also
suppress
infiltr
macrophag
neutrophil
product
tumor
necrosi
factor
tnf
interleukin
il
transform
growth
factor
tgf
intercellular
adhes
molecul
inhibit
activ
mous
obstruct
find
indic
paclitaxel
suppress
renal
interstiti
fibrosi
via
inhibit
pathway
product
proinflammatori
cytokin
find
studi
indic
addit
clinic
use
anticanc
agent
paclitaxel
may
repres
new
agent
manag
renal
fibrosi
indic
discoveri
therapeut
switch
drug
approv
clinic
use
may
use
new
indic
process
call
drug
reposit
drug
drug
reposit
differ
drug
coincid
serendip
aris
unintent
mishap
drug
discoveri
process
exemplifi
drug
sildenafil
thalidomid
apart
stagger
manufactur
cost
time
reduct
drug
reposit
facilit
drug
discoveri
overcom
bottleneck
therapeut
develop
process
prolong
patent
life
therebi
obtain
largest
invest
return
throughout
develop
process
coupl
significantli
higher
rate
success
reduc
develop
risk
benefit
drug
reposit
patient
evid
newli
aris
diseas
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
threaten
human
be
treat
exist
drug
establish
pharmacokinet
formul
safeti
data
anim
human
specif
reposit
potenti
display
associ
drug
reposit
may
tremend
decreas
overal
develop
time
year
decreas
total
cost
attrit
rate
increas
number
success
drug
reposit
exampl
colesevelam
bile
acid
sequestr
origin
develop
adjunct
diet
exercis
decreas
elev
lowdens
lipoprotein
cholesterol
patient
primari
hyperlipidemia
monotherapi
also
gain
approv
food
drug
administr
fda
treat
type
diabet
mellitu
unknown
mechan
gabapentin
pregabalin
origin
develop
antiepilept
agent
approv
fda
treat
anxieti
disord
neuropath
multipl
technic
approach
drug
reposit
diseas
drugderiv
approach
employ
avail
data
relat
diseas
knowledg
drug
interact
biolog
system
molecular
cellular
level
identifi
potenti
new
indic
exist
comput
method
wide
appli
explor
interactom
drug
offtarget
advers
drug
effect
provid
clue
new
indic
furthermor
genomewid
associ
studi
gwa
medic
genet
data
system
biolog
approach
use
conduct
drug
gwa
data
provid
insight
biolog
patholog
diseas
via
bioinformat
network
analysi
may
translat
potenti
new
therapeut
target
hit
approv
drug
sinc
patholog
often
share
diseas
exist
drug
known
target
retest
possibl
new
indic
genom
express
data
combin
vitro
drug
screen
target
verif
studi
provid
insight
mechan
action
drug
thu
becom
wide
use
drug
recent
explor
predict
advers
drug
reaction
adr
base
druginduc
geneexpress
profil
cultur
human
cell
connect
map
cmap
result
show
drug
induc
compar
adr
gener
lead
similar
cmap
express
profil
basi
express
associ
establish
predict
model
variou
adr
includ
sever
myocardi
infecti
event
drug
fda
box
warn
safeti
liabil
identifi
therefor
suggest
druginduc
gene
express
chang
combin
comput
method
may
offer
new
way
facilit
systemat
drug
safeti
evalu
drug
reposit
anoth
studi
demonstr
ontarget
offtarget
effect
drug
could
character
druginduc
vitro
genom
express
data
case
famili
ligand
target
tend
interact
common
offtarget
may
help
increas
effici
indic
discoveri
explain
complic
mechan
action
drug
propos
cmap
express
similar
new
indic
interact
use
increas
product
drug
reposit
process
find
novel
therapeut
treat
cure
diseas
fundament
challeng
biomed
research
due
high
cost
failur
rate
drug
reposit
consid
promis
strategi
revit
slow
drug
discoveri
pipelin
due
shorter
develop
time
lower
failur
toxic
risk
although
drug
reposit
intrins
limit
repres
altern
pathway
achiev
therapeut
success
postgenom
era
